MARKHAM, ONTARIO--(Marketwire - July 9, 2012) - iFabric Corp (TSX VENTURE:IFA), hereinafter referred to as "iFabric" or the "Company", today announced that it has been granted the exclusive Canadian distribution rights for the USA patented Patient Gown by ECT Solutions LLC "ECT", Coral Springs, Florida. The ECT Patient Gown is currently pending patent approval in Canada.
The ECT Patient Gown is made of a cloth material with a secured back, large pockets and various slit openings. All of these openings are strategically placed allowing the bedside care provider to monitor the patient without having to expose them which allows the gown to fully and completely cover the patient. For more information, visit www.ectsolutions.info.
The lack of modesty provided by ordinary patient gowns is known to be a chief complaint at hospitals. http://en.wikipedia.org/wiki/Hospital_gown
The ECT Patient Gown is a thoughtfully designed gown that provides health care providers easy access while maintaining the dignity and privacy of the patient.
Designed by a nurse to help improve patient outcomes and increase nursing efficiency, the ECT Patient Gown allows drainage, feeding and central line tubes to pass through the gown so they are easily visible during bedside care, reducing the risk of misconnections. One size fits most patients and a generous overlap in the back eliminates the need to put two gowns on the patient in order to protect the patient's modesty. Built-in central line slits separate lumens from the skin helping to minimize the risk of infections. Drain line and PEG tube slits prevent stress on insertion sites minimizing the need for re-applying dressings. Large pockets hold drains, pain pumps, etc., for easier patient ambulation.
A further benefit of this agreement is that ECT will be integrating iFabric's CLINIWEAVE anti-microbial technology in its product line.
"After extensive review of available anti-microbials, ECT chose iFabric's CLINIWEAVE anti-microbial technology for its class leading performance" stated Mrs. Chantale Trouillot, President of ECT Solutions LLC.
"The ECT Gown, impregnated with Cliniweave, is another vehicle that not only promotes our anti-microbial technology, but expands our product base for value added revenue," added Mr. Hylton Karon, President and CEO of iFabric.
CLINIWEAVE is effective against a wide range of micro-organisms including mold, mildew, fungi and odor causing bacteria. It provides long-term, effective control of microorganisms. This efficacy and safety has been documented in numerous peer reviewed publications, trade articles and certified tests. It is durable to deterioration through repeated washing and is clinically proven to kill bacteria associated with hospital acquired infections.
Medical uses for Cliniweave include bedding, curtaining, air filters, scrubs, masks and surfaces amongst others.
ABOUT iFABRIC CORP:
iFABRIC CORP currently has 25.2 million shares issued and outstanding. iFABRIC is a manufacturer, distributor, licensor and licensee of ladies intimate apparel products and accessories as well proprietary chemical compounds that render fabrics intelligent, thereby improving the safety and well-being of the wearer.
Forward-looking statements provide an opinion as to the effect of certain events and trends on the business. Certain statements contained in this news release constitute forward looking statements. The use of any words such as "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Forward-looking information includes, but is not limited to, statements with respect to the development potential of the Company's products.
Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Readers are cautioned not to place undue reliance on these statements as the Company's actual results, performance, or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that forward-looking statements will materialize. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or any other reason except as required by applicable securities laws.
Any financial outlook or future oriented financial information in this news release, as defined by applicable securities legislation, has been approved by management of iFabric. Such financial outlook or future oriented financial information is provided for the purpose of providing information about management's reasonable expectations as to the anticipated results of its proposed business activities. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The forward-looking statements contained in this press release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.